Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo

The authors created a chimeric antigen-receptor (CAR) that was capable of on-demand downregulation by fusing the CAR to a previously developed ligand-induced degradation domain. Addition of a small molecule ligand triggered exposure of a cryptic degron within the ligand-induced degradation domain (LID), resulting in proteasomal degradation of the CAR-LID fusion protein and loss of CAR on the surface of T cells.
[Molecular Therapy]
Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo: Molecular Therapy. (n.d.). Retrieved June 16, 2020, from https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(20)30294-X Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share
Share